

The Top 10 unrestricted shareholders of tradable shares

Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
Shen Fei He Technology (Group) Co., Ltd.	920,641,314	RMB ordinary shares
HKSCC NOMINEES LIMITED ()	335,255,500	Ordinary shares
China Infrastructure Co., Ltd. — Domestic — Priority — 005L — FH002 Shares	37,868,964	RMB ordinary shares
China Construction Bank — Huaihua Lushan Securities Investment Fund	32,188,808	RMB ordinary shares
Infrastructure Construction Bank of China — Huaihua Securities Investment Fund	21,318,308	RMB ordinary shares
Infrastructure Construction Bank of China — Jiangsu Grand Canal Waterway Construction Securities Investment Fund	19,120,000	RMB ordinary shares
China Merchants Bank Co., Ltd. — Everbright Bond Strategy Assets Securities Investment Fund	18,110,252	RMB ordinary shares
National Securities Fund 104	16,599,805	RMB ordinary shares
Bank of China — Priority Shares 50 Ordinary Securities Investment Fund	10,199,839	RMB ordinary shares
Bank of China — Assets Securities Investment Fund	10,000,000	RMB ordinary shares
<p align="center">Domestic ordinary shares Ordinary shares</p>		<p>Thirteen of Infrastructure Construction Bank of China — Huaihua Securities Investment Fund; Securities Investment Fund; Infrastructure Construction Bank of China — Jiangsu Grand Canal Waterway Construction Securities Investment Fund; RMB ordinary shares of Infrastructure Construction Bank of China; Thirteen of Bank of China — Priority Shares 50 Ordinary Securities Investment Fund; Bank of China — Assets Securities Investment Fund; RMB ordinary shares of Bank of China; Thirteen of China Construction Bank — Huaihua Lushan Securities Investment Fund; Bank of China — Assets Securities Investment Fund; RMB ordinary shares of Huaihua Financial Management Co., Ltd.; Thirteen of National Securities Fund 104; Bank of China — Priority Shares 50 Ordinary Securities Investment Fund; RMB ordinary shares of Everbright Financial Management Co., Ltd.; Th</p>

§3 SIGNIFICANT EVENTS

3.1 Significant events in the period from January 1st to December 31st of the reporting period are as follows:

A Significant event Not a Significant event

Unit: million RMB

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Current assets	2,485,783,000.50	4,972,524,758.70	-50%	Mainly due to the decrease in cash and cash equivalents in 2013.
Trade receivables	1,316,781,579.78	907,307,576.06	45%	Mainly due to the increase in trade receivables in 2013.
Inventory	7,615,057.77	17,674,707.55	-57%	Mainly due to the decrease in inventory in 2013.
Intangible assets	2,368,367,750.12	1,752,799,860.87	35%	Mainly due to the increase in intangible assets in 2013.
Development expenditure	42,946,124.18	29,475,413.33	46%	Mainly due to the increase in R&D expenditure in 2013.
Goodwill	2,710,407,586.05	1,661,770,763.96	63%	Mainly due to the increase in goodwill in 2013.
Other non-current assets	236,069,350.21	100,654,101.39	135%	Mainly due to the increase in other non-current assets in 2013.
Deferred tax assets	72,033,067.63	31,482,514.80	129%	Mainly due to the increase in deferred tax assets in 2013.
Share receivables	1,199,559,074.08	519,422,250.00	131%	Mainly due to the increase in share receivables in 2013.
Due to related parties	12,240,519.57	4,725,748.28	159%	Mainly due to the increase in due to related parties in 2013.
Other current assets	33,196,473.53	526,384,431.15	-94%	Mainly due to the decrease in other current assets in 2013.

Income Statement				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Operating Profit	7,070,780,938.31	5,387,845,935.96	31%	Mainly due to the increase in the contribution margin of the main products and the increase in the operating profit of the main products.
Operating Loss	3,957,631,876.59	3,005,217,397.09	32%	Mainly due to the increase in the contribution margin of the main products and the increase in the operating profit of the main products.
Gain from business disposal (net)	39,511,717.28	-14,636,854.56	N/A	Mainly due to the increase in the contribution margin of the main products and the increase in the operating profit of the main products.
Income	313,206,671.22	202,061,631.73	55%	Mainly due to the increase in the contribution margin of the main products and the increase in the operating profit of the main products.
Net Profit	72,257,721.95	33,558,889.22	115%	Mainly due to the increase in the contribution margin of the main products and the increase in the operating profit of the main products.
Other comprehensive income	285,252,496.15	-436,322,994.17	N/A	Mainly due to the increase in the contribution margin of the main products and the increase in the operating profit of the main products.

Statement of Cash Flow				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Net cash flow	-1,757,461,995.58	-368,977,652.38	376%	Mainly due to the increase in the contribution margin of the main products and the increase in the operating profit of the main products.

3.2 A. ... f b r r r ... f m J r ...

√ A ... b □ N ... b

O. 26 S ... b r 2013, b f f b ... (r r r r) f b ... b ... f b B r ... b 2013 3r ... (r r r r) f b ... b ... f b S r ... r C ... , b ... r ... r ... b ... r ... f R r ... S p r I ... S b ... (r r) f S p ... b ... F ... P r ... (G r ...) C . , L . * . O . 25 O . b r 2013, b CSRC ... r f b j ... f r b “ O ... b S p ... b F ... P r ... (G r ...) C . , L . R r ... A S p r I ... S b ... ” (S p ... S p ... B r H . 2013 N . 774) . A ... r ... b f ... b ... f b CSRC, b B r ... , ... r ... b ... r ... b ... r ... b ... R r ... S p r I ... S b ... (r ... r r) f S p ... b F ... P r ... (G r ...) C . , L . * b ... b ... r ... f b C ... T b ... b ... (r r r r) f b ... b ... f b B r ... b 2013 f r b ... (r r r r) f b ... b ... f

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharmaceutical Group) is a leading pharmaceutical company in China. The company's products are widely used in the treatment of various diseases. The company's products are widely used in the treatment of various diseases.

3.3 Fosun Pharmaceutical (Group) Co., Ltd. is a leading pharmaceutical company in China. The company's products are widely used in the treatment of various diseases.

Fosun Pharmaceutical (Group) Co., Ltd. is a leading pharmaceutical company in China. The company's products are widely used in the treatment of various diseases.

3.4 Fosun Pharmaceutical (Group) Co., Ltd. is a leading pharmaceutical company in China. The company's products are widely used in the treatment of various diseases. The company's products are widely used in the treatment of various diseases.

Fosun Pharmaceutical (Group) Co., Ltd. is a leading pharmaceutical company in China. The company's products are widely used in the treatment of various diseases.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Legal Representative: **Chen Qiyu**

30 October 2013

Consolidated balance sheet (Continued)

30th 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
Paid-up capital (attributable to shareholders)	2,240,462,364.00	2,240,462,364.00
Reserves	4,396,998,107.25	4,287,287,930.01
Retained earnings		
Share premium		
Surplus	1,338,476,598.49	1,338,476,598.49
Goodwill		
Unrealized gains	6,621,610,997.36	5,703,028,462.15
Financial instruments at fair value	-4,289,492.31	-10,462,767.38
Total equity attributable to shareholders	14,593,258,574.79	13,558,792,587.27
Minority interest	1,889,445,595.04	1,745,855,848.86
Total equity attributable to owners	16,482,704,169.83	15,304,648,436.13
Total liabilities and equity attributable to owners	27,589,580,696.34	25,507,140,466.01

Liabilities attributable to shareholders:
 Current: Current

Capital Finance: Finance:
 H. Finance, J.

Debt attributable to shareholders:
 Debt: Finance, J.

Balance sheet of the Parent Company

30th 2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Tenthousand Yuan

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and bank balances	967,810,425.06	2,804,108,583.37
Financial assets		
Receivables		
Prepaid expenses		
Inventory	112,185,785.22	98,972,778.68
Due from related parties	24,240,000.00	
Other receivables	1,207,151,982.57	941,562,545.17
Intangible assets	517,042.01	516,409.53
Non-current financial assets		
Other receivables	280,000,000.00	250,000,000.00
Total current assets	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
Available-for-sale financial assets		
Holdings		
Long-term receivables		
Long-term investments	5,471,340,934.74	4,173,763,622.82
Intangible assets		
Fixed assets	20,153,012.47	20,815,349.96
Construction in progress		
Prepaid expenses		
Deferred tax assets		
Prepaid taxes		
Other non-current assets		
Intangible assets	3,215,662.67	3,496,198.41
Deferred tax liabilities		
Goodwill		
Long-term financial liabilities		
Deferred tax liabilities		
Other non-current liabilities	4,470,831,299.40	4,035,133,683.09
Total non-current assets	9,965,540,909.28	8,233,208,854.28
Total	12,557,446,144.14	12,328,369,171.03

Balance sheet of the Parent Company (Continued)

30th 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Supplier accounts		
Financial institutions		
Bank		
Trade		
Reserves		
Interest	26,138,331.81	29,108,232.08
Taxes	16,833,088.84	5,188,721.77
Interest	155,509,208.37	152,405,396.96
Dividends		
Other	554,584,851.12	46,800,203.98
Non-current liabilities	360,000,000.00	355,000,000.00
Other		499,375,000.00
Total	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
Loans	125,000,000.00	165,000,000.00
Bank	4,070,832,033.25	4,063,347,254.54
Loans		
Suppliers		
Assets		
Deferred		
Other	2,275,000.00	2,500,000.00
Total	4,198,107,033.25	4,230,847,254.54
Total	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):		
Preference (redeemable)	2,240,462,364.00	2,240,462,364.00
Current	3,754,014,307.53	3,755,009,519.04
Loans		
Suppliers		
Share	305,635,420.68	305,635,420.68
Government		
Unrealized	946,161,538.54	708,537,057.98
Total	7,246,273,630.75	7,009,644,361.70
Total	12,557,446,144.14	12,328,369,171.03

Liabilities: Current

Capital: Fixed

Debt: Current

4.2

Consolidated Income Statement

J — 2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Tenthousand Yuan

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Total revenue	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income: Operating revenue	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income				
Expense				
Financial expense				
II. Total expense	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
Income: Operating expense	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
Income				
Financial expense				
Provision				
Cost				
Non-recurring expense				
Provision				
Administrative expense				
Brand amortization	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
Share of profit	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
Asset impairment	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
Financial income	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
Asset impairment	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Provision: Government subsidy	-548,949.75	-4,627,534.57	39,511,717.28	-14,636,854.56
Income (“-”)	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
Income: Government				
Income: Government	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
Financial income (“-”)				
III. Operating profit (“-”)	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Provision: Non-recurring	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
Loss: Non-recurring	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
Income: Loss	260,198.27	-243,201.72	979,886.77	946,040.98

Income Statement of the Parent Company

July – September 2013

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Thousand Yuan

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Operating Profit				
Loss from operations				
Business income				
Sales income				
Administrative income	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
Financial income	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
Administrative expense				
Profit from disposal of long-term assets				
Loss from disposal of long-term assets				
Income from disposal of long-term assets	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
Income from disposal of long-term assets	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Operating Profit ("–")	-34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
Profit from non-current assets	76,900.00	234,093.38	236,049.11	734,093.38
Loss from non-current assets		-570,000.00	2,514,544.42	860,000.00
Income from long-term assets			5,725.77	
III. Total Profit ("–")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Loss				
IV. Net Profit ("–")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Earnings				
(1) basic earnings				
(2) diluted earnings				
I. Other comprehensive income			51,779.40	27,699,470.25
II. Total comprehensive income	-34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chief Financial Officer:

Director of Accounting:

Company: Fosun Pharmaceutical (Group) Co., Ltd.

Head of Finance:

Director of Accounting:

Consolidated Statement of Cash Flow (Continued)

J - 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
II. Cash flow generated from investing activities (Continued):		
Cash flow from the sale of property, plant and equipment	711,664,658.89	839,693,736.40
Cash flow from the sale of investments	251,949,461.45	734,761,521.45
Net cash flow from investing activities	2,011,879,515.78	9,072,797.31
Operating activities	100,020,349.23	9,072,797.31
Subsidiary financing	3,075,513,985.35	1,583,528,055.16
Net change in cash and cash equivalents	-1,757,461,995.58	-368,977,652.38
III. Cash flow generated from financing activities:		
Cash flow from the issuance of debt	2,088,710.98	761,199.00
Interest on debt	2,088,710.98	761,199.00
Cash flow from the sale of equity	1,302,361,982.24	1,022,152,808.76
Cash flow from the sale of assets	329,448,475.13	262,541,891.46
Subsidiary financing	1,633,899,168.35	2,772,405,899.22
Cash flow from the sale of investments	1,221,891,677.53	2,628,044,486.20
Cash flow from the sale of property, plant and equipment	950,844,046.86	601,916,917.03
Interest on debt	702,264,204.84	366,813,171.49
Operating activities	48,488,630.70	101,408,014.93
Subsidiary financing	2,221,224,355.09	3,331,369,418.16
Net change in cash and cash equivalents	-587,325,186.74	-558,963,518.94
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-25,426,268.76	-4,569,909.53
V. Net increase of cash and cash equivalents	-1,902,809,425.34	-517,020,589.16
Period beginning balance	4,171,574,742.12	2,428,219,484.36
VI. Closing balance of cash and cash equivalents	2,268,765,316.78	1,911,198,895.20

L. R. R. f. b.
C. Q.

C. f. F. G.
H. f. J.

D. r. f. b. A.
D. r. J.

Statement of Cash Flow of the Parent Company (Continued)

J - 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
III. Cash flow generated from financing activities:		
Cash flow from operations		
Cash flow from borrowings	255,115,078.77	
Cash flow from investments		1,486,950,000.00
Operating activities	1,904,031,173.98	4,295,169,165.49
Subsidiary financing activities	2,159,146,252.75	5,782,119,165.49
Cash flow from borrowings	790,115,078.77	454,000,000.00
Cash flow from investments	674,744,025.09	302,177,196.32
Operating activities	2,109,471,293.35	5,478,222,986.00
Subsidiary financing activities	3,574,330,397.21	6,234,400,182.32
Net change in cash and cash equivalents	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
Period beginning balance	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

L. R. ...
C. ...

Cash Flow ...
H. ...

Dr. ...
D. ...